D. E. Shaw & Co., Inc. Anavex Life Sciences Corp. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 105,130 shares of AVXL stock, worth $917,784. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,130

Holding current value

$917,784

% of portfolio

0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$5.11 - $12.56 $537,214 - $1.32 Million	105,130 New	105,130 $1.13 Million
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $38,181 - $56,540	-11,263 Reduced 16.18%	58,355 $246,000
Q1 2024 May 15, 2024	BUY	$4.55 - $6.75 $73,546 - $109,107	16,164 Added 30.24%	69,618 $354,000
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $105,401 - $208,084	20,913 Added 64.27%	53,454 $497,000
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $82,287 - $117,715	-12,563 Reduced 27.85%	32,541 $213,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $345,496 - $428,488	45,104 New	45,104 $366,000
Q4 2022 Feb 14, 2023	SELL	$7.65 - $14.43 $1.97 Million - $3.72 Million	-257,959 Reduced 84.81%	46,190 $427,000
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $651,524 - $941,416	-73,205 Reduced 19.4%	304,149 $3.14 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $496,802 - $872,632	67,962 Added 21.97%	377,354 $3.78 Million
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $2.85 Million - $5.18 Million	292,864 Added 1771.93%	309,392 $3.81 Million
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $478,564 - $660,861	-28,351 Reduced 63.17%	16,528 $287,000
Q3 2021 Nov 15, 2021	SELL	$16.82 - $25.75 $921,971 - $1.41 Million	-54,814 Reduced 54.98%	44,879 $806,000
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $490,159 - $1.39 Million	48,244 Added 93.77%	99,693 $2.28 Million
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $265,991 - $829,872	51,449 New	51,449 $769,000
Q3 2020 Nov 16, 2020	SELL	$3.8 - $5.0 $118,541 - $155,975	-31,195 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.62 - $5.2 $77,455 - $153,727	-29,563 Reduced 48.66%	31,195 $153,000
Q1 2020 May 15, 2020	SELL	$2.38 - $5.81 $25,684 - $62,701	-10,792 Reduced 15.08%	60,758 $191,000
Q4 2019 Feb 14, 2020	BUY	$2.31 - $3.14 $165,280 - $224,667	71,550 New	71,550 $185,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.9 $79,003 - $138,789	-35,587 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.75 - $3.7 $97,864 - $131,671	35,587 New	35,587 $120,000
Q1 2018 May 15, 2018	SELL	$2.32 - $3.44 $37,444 - $55,521	-16,140 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.12 - $4.94 $50,356 - $79,731	16,140	16,140 $52,000

Others Institutions Holding AVXL

# of Institutions

188

Shares Held

29.2M

Call Options Held

894K

Put Options Held

821K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $680M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account